
-
Kezar Life Sciences NasdaqCM:KZR Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Location: 4000 Shoreline Court, South San Francisco, CA, 94080, United States | Website: https://www.kezarlifesciences.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-71.54M
Cash
114.4M
Avg Qtr Burn
-17.14M
Short % of Float
1.41%
Insider Ownership
11.57%
Institutional Own.
59.28%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zetomipzomib (KZR-616) Details Autoimmune Hepatitis | Phase 2a Update | |
KZR-261 Details Solid tumor/s, Melanoma | Phase 1 Data readout | |
KZR-616 Details Chronic inflammatory disorder, Inflammatory disease, Autoimmune disease | Failed Discontinued | |
Zetomipzomib (KZR-616) Details Chronic inflammatory disorder, Chronic kidney disease, Inflammatory disease, Kidney disease, Lupus nephritis | Failed Discontinued |